Citations

Clear

845 citation(s) found for "Dickson, DW".

SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.
Riedel, Richard F. , Riedel, Richard F , Dickson, Mark A. , Ballman, Karla V. , Weiss, Mia C. , Attia, Steven , Pollack, Seth M. , Choy, Edwin , Wagner, Andrew J. , Wilky, Breelyn A , Davis, Lara E. , Koff, Andrew, Tap, William D.

Mayo Clinic

Journal of Clinical Oncology | June 3, 2026 | Volume: 44 | Issue: 17_suppl | Pages: No page available

10.1200/jco.2026.44.17_suppl.lba2 Get It

LBA2 Background: Dedifferentiated liposarcoma (DDLS) remains a difficult disease to treat with limited systemic therapy options. Approved drugs offer modest benefit such as trabectedin (median progression-free survival [mPFS] 2.2 months [m]) or eribulin (mPFS 2.0m). The Cyclin-dependent kinase 4 (CDK4) oncogene is ubiquitously amplified in DDLS and is a rational therapeutic target. In single-arm phase 2 studies, treatment with selective CDK4 inhibitors resulted in mPFS 4.2m with palbociclib and mPFS 7.7m with abemaciclib. We hypothesized that treatment with abemaciclib would improve PFS compared to placebo in patients with recurrent or metastatic DDLS. Methods: SARC041 was a phase 3 randomized double-blind study of abemaciclib versus placebo. The study was open at 9 academic medical centers in the USA. Eligible patients (pts) had recurrent or metastatic DDLS (purely well-differentiated liposarcoma excluded), progression of disease by RECIST 1.1 in the 6 months prior to study entry, any number of prior systemic therapies, and adequate organ function and performance status. Pts were stratified by prior lines of therapy (0 vs 1 or more) and randomized 1:1 between abemaciclib 200 mg PO twice a day or matching placebo. Scans were every 6 weeks (every 12 weeks after week 36) and pts with progression of disease on placebo could cross over to open label abemaciclib. The primary endpoint was PFS. The design provided 80% power with two-sided 10% significance level to detect a hazard ratio of 0.6 by log-rank test. Secondary endpoints were overall response rate (ORR), PFS and response rate after crossover, and overall survival (OS). Data cutoff was March 1, 2026. Results: In total, 108 pts were randomized to receive abemaciclib (n = 54) or placebo (n = 54). Demographic/baseline characteristics were generally similar across treatment arms. Abemaciclib demonstrated a statistically significant improvement in PFS at 9.67m vs placebo at 1.52m (hazard ratio [HR] 0.39; 95% confidence interval [CI], 0.25–0.59; p < 0.001). ORR was 9.3% for abemaciclib vs 0% for placebo (p = 0.057). mOS was not reached with abemaciclib vs 25.45m with placebo (HR 0.55; 95% CI, 0.28–1.07; p = 0.077). mPFS after crossover from placebo to abemaciclib was 3.44m (95% CI 2.66, 6.84). ORR after crossover was 4.3% (95% CI 0.53%, 15%). mOS after crossover was 24.03m (95% CI: 11.7, NA). Grade 3 or higher adverse event rates were similar in both arms (p > 0.99). No new safety signals were observed. Conclusions: Abemaciclib demonstrated a statistically significant improvement in PFS vs placebo in pts with dedifferentiated liposarcoma, with an encouraging OS trend. These results support abemaciclib as a new treatment option for dedifferentiated liposarcoma. Clinical trial information: NCT04967521 .
Multimodal analysis of cell-free DNA identifies epigenetic biomarkers for amyotrophic lateral sclerosis diagnosis and progression
Michels, Sebastian, Chen, Chaorong, Ruf, Wolfgang P., Garcia, M. Madhy Garcia, Arnold, Frederick J. , Wu, Zhuoxing, Bennett, Craig L. , Shams, Daniel, Thompson, Leslie M., Dickson, Dennis W., Petrucelli, Leonard, Dorst, Johannes, Li, Wei, Spada, Albert R. La, Walker, Alyssa C. , Bennett, Craig L , Michels, Sebastian , Ruf, Wolfgang Philipp , Thompson, Leslie Michels , Dickson, Dennis W. , Petrucelli, Leonard , Dorst, Johannes , Prudencio, Mercedes , Spada, Albert R. La

Mayo Clinic

Journal of Clinical Investigation | June 1, 2026 | Volume: 136 | Issue: 11 | Pages: No page available

10.1172/jci191508 | PMID 42222887 Get It

The role of the epigenome in age-related neurodegenerative disorders remains understudied. Here, we analyzed circulating cell-free DNA (cfDNA) from blood to detect methylation changes as a liquid biopsy for Amyotrophic Lateral Sclerosis (ALS). Our study included 20 patients with sporadic ALS, 10 patients with C9orf72-associated ALS, 10 asymptomatic carriers of the C9orf72 repeat expansion mutation, and 21 nondisease control individuals. Following targeted enzymatic methyl-sequencing (EM-seq) of approximately 4 million CpG sites, we detected numerous differentially methylated genes, including several implicated in ALS disease risk and pathogenesis. By integrating multiple epigenetic features, we delineated a distinct epigenetic signature, which achieved an average area under the curve (AUC) of 0.91 ± 0.10 upon receiver operator characteristic (ROC) analysis, which enabled detection of approximately 70% of patients with ALS with close to 100% specificity. Furthermore, we also identified a set of genes whose methylation status significantly correlated with clinical disease progression and cerebrospinal fluid (CSF) neurofilament levels. Our results reveal the potential of cfDNA-based biomarkers to accurately diagnose ALS and potentially predict disease progression.
Vascular endothelial growth factor receptor-1 (VEGFR-1) knock-down is protective against hypoxia, Aβ1-42 oligomer and Aβ1-42 fibril -induced neuronal cell death: implications in AD pathogenesis
Li, Zonghua , Rachamala, Hari Krishnareddy, Castanedes-Casey, Monica, Kulkarni, Tanmay, Chakravarty, Trisha, Dutta, Shamit, Wang, Enfeng , Dickson, Dennis, Mukhopadhyay, Debabrata, Das, Pritam , Angom, Ramcharan Singh , Rachamala, Hari Krishnareddy, Castanedes‐Casey, Monica , Mukhopadhyay, Debabrata

Mayo Clinic

Frontiers in Neuroscience | May 29, 2026 | Volume: 20 | Issue: No issue available | Pages: No page available

10.3389/fnins.2026.1799391 | PMID 42292330 Get It

Introduction Recent transcriptome analysis has demonstrated increased expression of Vascular Endothelial Growth Factor receptor-1 (VEGFR-1/FLT1) and in AD brain. Increased expression of VEGFR1 and its ligand VEGFB were associated with a more rapid rate of cognitive decline, providing evidence of a potential link between increased VEGFR-1 expression in AD pathogenesis. In this study, we explored the potential role of VEGFR-1 expression in neurons on AD pathology. Methods To confirm VEGFR1 expression in AD brains, we first performed immunostaining in AD brain sections (AD - Braak stage V-VI, and normal controls - Braak 0-II). And to determine a potential detrimental role of neuronal VEGFR1 expression on AD associated pathologies, we exposed SH-SY5Y human neuroblastoma cells and mouse primary neurons to either hypoxia conditions (1%O 2 ) or 5 μ Aβ1-42 oligomers or fibrils for 24, 28 and 72hrs. Results In this study, we found preferential staining of VEGFR-1 in the neuropil and neuronal cell bodies both in AD and Control hippocampus and increased VEGFR-1 immunoreactivity in dystrophic neuritic processes in the vicinity of Thio-S positive amyloid plaques in AD brains. And treatment of SH-SY5Y human neuroblastoma cell line and mouse primary neurons, with either hypoxia conditions or Aβ1-42 oligomers, resulted in increased VEGFR-1 expression and cleaved caspase 3 activation, leading to neuronal toxicities/cell death. Similarly, treatment with Aβ1-42 fibrils also increased VEGFR-1 and cleaved caspase 3 protein levels in the SH-SY5Y cells whereas treatment with Aβ1-42 monomers had no effect on VEGFR-1 expression. In addition, we show that over-expression of VEGFR-1 intracellular domains in SH-SY5Y cells directly induced neuronal toxicities and importantly, siRNA-mediated knockdown of VEGFR-1 in neurons prevented the hypoxia, Aβ1-42 oligomer and Aβ1-42 fibril-induced toxicities and cell death phenotypes. Treatment with either hypoxia or Aβ1-42 oligomers also reduced expression of cell survival genes including VEGFR-2 and Hippo pathway YAP1 and siRNA-mediated VEGFR-1 knockdown in the neurons normalized expression of both VEGFR-2 and YAP1. Using differential gene expression analysis, we demonstrated upregulation of several inflammatory/interferon-stimulated genes (ISGs) as well as increased expression of genes involved in activation of oxidative stress and cell death pathways in response to Aβ1-42 oligomers treatment in mouse primary neurons. And siRNA-mediated VEGFR-1 knockdown in the mouse primary neurons, reduced gene expression of both the ISGs and oxidative stress/cell death pathways in response to Aβ1-42 oligomer treatment. Discussion In summary, these results show that siRNA-mediated knockdown of VEGFR-1 in neurons significantly prevented hypoxia, Aβ1-42 oligomer and Aβ1-42 fibril-induced cellular toxicities and cell death phenotypes, indicating a potential detrimental role of aberrant VEGFR-1 expression and signaling in response to AD associated pathologies.
Abnormal amyloid PET usually represents intermediate/high Alzheimer's disease neuropathologic change
Burkett, Brian J. , Wiste, Heather J. , Johnson, D H, Boeve, Bradley F., Kantarci, Kejal, Petersen, Ronald C., Knopman, David S., Vemuri, Prashanthi, Graff‐Radford, Jonathan, Lowe, Val, Cogswell, Petrice M., Pillai, Jay, Schwarz, Christopher G., Murray, Melissa E., Dickson, Dennis W., Jack, Clifford R., Pillai, Jay J. , Burkett, Brian , Pillai, Jay J , Boeve, Bradley F. , Kantarci, Kejal , Petersen, Ronald C. , Knopman, David S. , Vemuri, Prashanthi , Graff‐Radford, Jonathan , Lowe, Val J. , Cogswell, Petrice M. , Schwarz, Christopher G. , Nguyen, Aivi T. , Murray, Melissa E. , Dickson, Dennis W. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | May 7, 2026 | Volume: 22 | Issue: 5 | Pages: No page available

10.1002/alz.71449 | PMID 42092343 Get It

Abstract INTRODUCTION Alzheimer's disease neuropathologic change (ADNC) classification identifies not/low and intermediate/high levels of neuropathology. Our goal was to assess how frequently a positive amyloid positron emission tomography (PET) scan indicates not/low ADNC and whether this autopsy finding can occur >10 years after a positive amyloid PET. METHODS Participants with positive amyloid PET scans were categorized by levels of ADNC at autopsy, grouped by time from initial positive amyloid PET to time of death (<5 years, 5 to <10 years, or 10+ years). RESULTS Among those with a positive amyloid PET scan, the majority had intermediate/high ADNC at autopsy (234/259, 90%). In the group with 10+ years between a positive amyloid PET and death ( n = 39) not/low ADNC occurred in 3/39 (8%). DISCUSSION Not/low ADNC is uncommon among those with positive amyloid PET scans. After 10+ years, it is possible but rare for a positive amyloid PET scan to represent an indolent state of neuropathology.
Seeing Invisible Oligomers: Rethinking α‐Synuclein Pathology Through Proximity Ligation Assay
Jensen, Nanna Møller , Dickson, Dennis W. , Jensen, P Nøhr , Jensen, Poul Henning , Sekiya, Hiroaki , Jensen, Nanna Møller , Dickson, Dennis W , Sekiya, Hiroaki

Mayo Clinic

Movement Disorders | April 27, 2026 | Volume: 41 | Issue: 7 | Pages: 1680-1689

10.1002/mds.70335 | PMID 42036389 Get It

Abstract Parkinson's disease (PD) and multiple system atrophy are defined by α‐synuclein (αSYN)‐positive inclusions – Lewy bodies (LBs) and glial cytoplasmic inclusions – yet mounting evidence indicates that these inclusions represent only a fraction of disease‐relevant pathology. αSYN exists in dynamic conformational states, and soluble oligomeric assemblies, often undetectable by conventional immunohistochemistry, are increasingly implicated as key neurotoxic species. The αSYN proximity ligation assay (αSYN‐PLA) enables in situ detection of widespread non‐inclusion oligomeric pathology across synucleinopathies. Notably, PLA studies in LRRK2 ‐associated PD demonstrate abundant oligomeric αSYN even in cases lacking LBs, challenging the centrality of inclusions in defining disease. In this Perspective, we outline the principles of αSYN‐PLA, discuss antibody strategies and structural implications of detected species, review current evidence – including LB‐negative LRRK2 ‐PD – and consider temporal dynamics and clinical applications of PLA‐positive aggregates as biomarkers and therapeutic targets. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Phosphorylated ubiquitin is a secondary messenger and an epigenetic mark mediating mitochondria to nucleus signaling
Mercer, Thomas J., Dániel, Bence , Fredrickson, Craig, Le, Daniel , Lee, Serena, Kulkarni, Vineet Vinay , Hou, Xu , Ngu, Hai , Jung, Min, Heon‐Roberts, Rachel , Smith, Amelia, Cheung, Tommy K. , Gastaldo, Denise , Jeong, Claire G. , Foreman, Oded , Bingöl, Bariş , Fiesel, Fabienne C , Ryan, Brent J , Dickson, Dennis W , Fiesel, Fabienne C. , Kameswaran, Vasumathi , Dickson, Dennis W. , Springer, Wolfdieter , Rose, Christopher M.

Mayo Clinic

No container title available | April 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.24.719390 | PMID 42079170 Get It

Abstract Parkinson’s disease (PD) is commonly associated with dysfunctional mitochondrial homeostasis. PINK1, a S/T kinase mutated in early-onset PD, generates phosphoserine 65 ubiquitin (pS65Ub) on damaged mitochondria facilitating their removal. Here, we show that pS65Ub translocates into the nucleus after generation at damaged mitochondria and is directly attached to substrates by resident E3 ligases. Histone H2A is a major substrate and is modified at lysine 119 (H2AK119) by the polycomb silencer, E3 ligase RING1B. At nucleosomes, pS65Ub simultaneously suppresses RING1B and potentiates H2A deubiquitinases USP16 and USP21. Epigenetic profiling and RNA sequencing reveal that pS65Ub is enriched at the promoters of poorly expressed yet dynamically regulated genes and is associated with H2AK119ub depletion. Functionally, we show that pS65Ub enrichment drives polycomb target gene expression, which accelerates the maturation of dopaminergic neurons. Importantly, post-mortem PD brains exhibit elevated nuclear pS65Ub, potentially linking nuclear pS65Ub accumulation with disease pathogenesis. Together, these data indicate that pS65Ub generated at damaged mitochondria regulates fundamental cellular processes at distant sites.
Biochemical and Immunohistochemical Associations of TDP ‐43 and Cryptic RNA With Hippocampal and Amygdala Volumetrics in Alzheimer's Disease
Gatto, Rodolfo G. , Ghayal, Nikhil B , Ayuso, Virginia Estades, Jansen‐West, Karen , Dunmore, Judith A. , Song, Yuping , Yue, Mei, Cook, Casey , DeTure, Michael , Rawlinson, Bailey, Castanedes‐Casey, Monica, Jack, Clifford R., Petersen, Ronald C. , Petrucelli, Leonard, Whitwell, Jennifer L. , Prudencio, Mercedes , Josephs, Keith A. , Youseff, Hossam , Ghayal, Nikhil B , Estades Ayuso, Virginia , Rawlinson, Bailey D, Petersen, Ronald C , Dickson, Dennis W , Whitwell, Jennifer , Josephs, Keith A , Prudencio, Mercedes , Whitwell, Jennifer L , Youssef, Hossam , Castanedes‐Casey, Monica , Jack, Clifford R. , Dickson, Dennis W. , Petrucelli, Leonard

Mayo Clinic

Annals of Neurology | April 9, 2026 | Volume: 100 | Issue: 1 | Pages: 193-205

10.1002/ana.78223 | PMID 41952326 Get It

Objective Immunohistochemically (IHC) measured transactive response DNA‐binding protein 43 (TDP‐43) inclusions are observed in Alzheimer's disease (AD) and are associated with medial temporal lobe atrophy. Accumulation of cryptic exons occurs in AD in response to TDP‐43 pathology. We aimed to assess relationships between IHC and biochemically measured insoluble TDP‐43 and cryptic exons and assess associations with hippocampal and amygdala volume loss and atrophy rates on magnetic resonance imaging (MRI). Methods Eighty‐one neuropathologically diagnosed AD cases were analyzed. For biochemistry, insoluble TDP‐43 was quantified using a Meso‐scale discovery (MSD) immunoassay. IHC‐TDP burden was quantified with digital histopathology. Cryptic RNAs were assessed via quantitative real‐time polymerase chain reaction (qRT‐PCR). Thirty‐eight cases had serial brain MRI. Hippocampal and amygdala volumes were calculated using FreeSurfer. Regression models were used to investigate associations among IHC‐TDP‐43 status/burden, MSD‐TDP status/levels, cryptic RNAs, and hippocampal and amygdala volumes and atrophy rates. Results IHC‐TDP(+) cases exhibited elevated levels of MSD‐TDP and cryptic RNAs ( KCNQ2 , STMN2 , and UNC13A ) and increased MSD‐TDP levels were associated with increased cryptic RNA levels, in the hippocampus and amygdala. IHC‐TDP(+) cases had smaller hippocampal and amygdala volumes compared to IHC‐TDP(−) cases. MSD‐TDP(+) cases had smaller hippocampal volumes and faster amygdala rates of atrophy compared with MSD‐TDP(−) cases. Higher KCNQ2 and UNC13A levels were associated with smaller amygdala volumes. Interpretation MSD‐TDP level is a reliable surrogate for IHC‐based TDP‐43 status. Both TDP‐43 and cryptic RNA levels are associated with reduced medial temporal volumes, suggesting cryptic exons may be playing a role in brain volume loss in AD. ANN NEUROL 2026;100:193–205
Neurodegeneration risk variants promote lysosomal TMEM106B fibril accumulation
Replogle, John, Marks, Jordan D. , Fernandez, Martin G , Yu, Dahyun , Winters, Elizabeth, Jawahar, Vidhya Maheswari, Deshmukh, Rishi, Sutanto, Renaldo, Kowal, Isabelle, Frankenfield, Ashley M. , Shi, Rachel , Carlomagno, Yari , Jansen-West, Karen, Kopach, Andrii , Ndayambaje, I. Sandra , Qi, Yue Andy, Shantaraman, Ananth, Pozo-Cabanell, Ignacio, Sheth, Udit , Yue, Mei, Duong, Duc, Bennett, David A, Damme, Markus, Boeve, Brad F, Day, Gregory S, Skarnes, William C, Petersen, Ronald C, Josephs, K., Graff-Radford, Neill, Barmada, Sami J. , Zhang, Yongjie, Hao, Ling , DeTure, Michael , Rawlinson, Bailey, Cook, Erica Engelberg, Casey, Monica Castanedes, Perez, Nathan M, Dickson, Dennis, Liu, Yue, Seyfried, Nicholas T., Wingo, Thomas S, Mosalaganti, Shyamal , Petrucelli, Leonard, Ward, Michael E, Ward, Michael E. , Replogle, John Michael , Todd, Tiffany W. , Engelberg-Cook, Erica , Perez, Nathan, Ward, Michael E , Barmada, Sami , Sheth, Udit , Yuan, Hebao , Kowal, Isabelle , Jansen‐West, Karen , Qi, Yue , Shantaraman, Anantharaman , Duong, Duc, Ferguson, Shawn M. , Bennett, David A. , Daμμe, Markus , Day, Gregory S. , Kellman, Benjamin P. , Skarnes, William C. , Petersen, Ronald C. , Graff‐Radford, Neill R. , McDonough, Justin A. , Prudencio, Mercedes , Dickson, Dennis W. , Wingo, Aliza P. , Liu, Yue, Seyfried, Nicholas T. , Wingo, Thomas S , Petrucelli, Leonard

Mayo Clinic

No container title available | March 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.26.714634 | PMID 41929000 Get It

Variants in TMEM106B and GRN , which encode lysosomal proteins, interact through unknown mechanisms to increase the risk of age-related cognitive decline and neurodegeneration. Here, we show that these variants converge on a single molecular intermediate: the cleaved intra-lysosomal fibril core of TMEM106B, a precursor to amyloid fibrils that accumulate in the aging brain. A protein-coding TMEM106B risk variant (p.T185) drives fibril core accumulation by impairing its degradation and GRN risk variants amplify this effect. Mice over-expressing the fibril core develop hallmarks of neurodegeneration, and cryo-electron tomography reveals intra-lysosomal fibrils in cultured neurons, mice, and diseased human brain. In GRN -mutation carriers, in whom fibril burden is greatest, fibrils extrude through ruptured lysosomal membranes. These findings identify intra-lysosomal TMEM106B fibrillization as a convergent neurodegeneration mechanism and potential therapeutic target.